Bayer requested a preliminary injunction over J&J’s Erleada marketing, arguing its headline survival claims rely on flawed real-world data, not clinical trials. The judge ruled that Bayer failed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results